سعر ميثوسيب 50مجم/2مل فيال 2022

Methotrexate 50 mg/2 mL (25 mg/mL) solution for injection, 1 vial; marketed in Egypt by Star International Company (manufactured by Cipla Ltd. (India)).

• Acute lymphoblastic leukaemia (combination chemotherapy)Population: Adults and childrenDailyMed (U.S. National Library of Medicine)
• Prophylaxis and treatment of meningeal leukaemiaPopulation: Adults and childrenDailyMed (U.S. National Library of Medicine)
• Non-Hodgkin lymphomaPopulation: Adults and childrenDailyMed (U.S. National Library of Medicine)

• In rheumatoid arthritis trials (7.5-15 mg weekly): elevated liver tests (15%), nausea/vomiting (10%), stomatitis, thrombocytopenia, rash/pruritus, diarrhoea, alopecia, leukopenia, pancytopenia, dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pregnancy in patients with non-neoplastic diseases.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• History of severe hypersensitivity reactions to methotrexate, including anaphylaxis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: embryo-fetal toxicity including fetal death; hypersensitivity reactions; serious adverse reactions including death (bone marrow, gastrointestinal, liver, lungs, skin, kidneys) - monitor closely and withhold or discontinue as appropriate. Formulations with benzyl alcohol can cause severe CNS toxicity or metabolic acidosis; use only preservative-free injection for neonates/low-birth-weight infants and intrathecal use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Myelosuppression, serious infections, gastrointestinal toxicity, hepatotoxicity (fibrosis/cirrhosis, risk increased with alcohol and cumulative dose), pulmonary toxicity, dermatologic reactions and renal toxicity can occur; administer folic or folinic acid as directed to reduce adverse reactions in non-neoplastic use.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Drugs increasing methotrexate exposure (oral antibiotics, penicillins, sulfonamides, highly protein-bound drugs, probenecid, proton pump inhibitors, salicylates and other weak acids, nephrotoxic drugs)May increase methotrexate concentrations and severe toxicity; monitor closely if coadministration cannot be avoided.DailyMed (U.S. National Library of Medicine)
• Nitrous oxide anaesthesiaPotentiates methotrexate effects on folate pathways; avoid.DailyMed (U.S. National Library of Medicine)
• Folic acid and derivativesDecrease methotrexate effectiveness in neoplastic diseases; take only as directed.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnancy for non-neoplastic diseases; can cause embryo-fetal toxicity and fetal death; advise patients with neoplastic disease of the risk; females and males of reproductive potential should use effective contraception.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Do not breastfeed during treatment and for 1 week after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Methotrexate: Inhibits dihydrofolate reductase, interfering with DNA synthesis, repair and cellular replication (US label).